Menu
Search
|

Menu

Close
X

Pluristem Therapeutics Inc PSTI.OQ (NASDAQ Stock Exchange Capital Market)

1.36 USD
-0.02 (-1.45%)
As of Feb 16
chart
Previous Close 1.38
Open 1.38
Volume 2,763
3m Avg Volume 94,659
Today’s High 1.38
Today’s Low 1.36
52 Week High 2.12
52 Week Low 1.06
Shares Outstanding (mil) 97.47
Market Capitalization (mil) 145.24
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
3
FY15
0
EPS (USD)
FY18
-0.154
FY17
-0.319
FY16
-0.292
FY15
-0.351
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
4.77
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-76.96
14.43
Return on Equity (TTM)
vs sector
-81.32
16.13

EXECUTIVE LEADERSHIP

Yaky Yanay
Chairman of the Board, Chief Executive Officer, Since 2017
Salary: $249,000.00
Bonus: --
Zalman Aberman
President, Co-Chief Executive Officer, Director, Since 2017
Salary: $484,400.00
Bonus: --
Erez Egozi
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Doron Shorrer
Lead Independent Director, Since 2006
Salary: --
Bonus: --
Moria Kwiat
Director, Since 2012
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Matam Advanced Technology Park
Building No. 5
HAIFA     31905

Phone: +97274.7108600

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

SPONSORED STORIES